Sonata Therapeutics is developing Network Medicines™ that reprogram diseased cells to release therapeutic signals, coordinating multicellular networks to drive disease resolution in cancer, fibrosis, and autoimmune disorders. This approach addresses the challenge of dysfunctional cell signaling in disease progression by enabling a targeted, holistic treatment strategy that enhances the efficacy of therapeutic interventions.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases, including cancer, fibrosis, and autoimmune disorders, are driven by dysfunctional cell signaling where diseased cells send pathologic signals to other cell types, perpetuating a cycle of dysfunction and disease progression. Traditional therapeutics often target only one cell type within the complex multicellular networks involved in these diseases.
Solution
Sonata Therapeutics is developing Network Medicines™, a class of therapeutics designed to reprogram diseased cells to release a defined array of signals that precisely coordinate multicellular networks to drive disease resolution. These Network Medicines have both a direct effect on diseased cells and a network effect, reprogramming those cells to release specific therapeutic signals that coordinate key cells in the network. This approach aims to modulate and coordinate all key players in the multicellular networks towards cure, addressing the limitations of therapeutics that only target one cell type.
Target Audience
The target audience includes patients suffering from cancer, fibrosis, and autoimmune disorders, as well as researchers and clinicians in these fields.
Features
- Network Medicines™ that reprogram diseased cells to become coordinators of cure.
- Designed to have both a direct effect on diseased cells themselves and a network effect.
- Platform systematically defines and assesses for Network Effects necessary to drive disease resolution upfront.